MICHELE KASSIEN: Open Payments
NPI 1184137747 · DOVER, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,216 in 62 payments from 12 companies in 2025. Trend: 2023 $123 · 2024 $1,081 · 2025 $1,216
Food & beverage: $1,116Education: $100
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 8 | $246 |
| Janssen Biotech, Inc. | 8 | $233 |
| ABBVIE INC. | 14 | $192 |
| UCB, Inc. | 10 | $147 |
| Galderma Laboratories, L.P. | 9 | $143 |
| Lilly USA, LLC | 3 | $68 |
| Amgen Inc. | 3 | $47 |
| LEO Pharma Inc. | 2 | $35 |
| Organon LLC | 1 | $34 |
| Arcutis Biotherapeutics, Inc. | 2 | $33 |
Products named: DUPIXENT, TREMFYA, Bimzelx, NEMLUVIO, SKYRIZI, RINVOQ, TALTZ, OTEZLA.
Industry payments across DE — which companies pay providers there.
